Deep Dive In Vitiligo

Discover the future of vitiligo treatment in our latest episode, where we spotlight cutting-edge therapies transforming care for this complex condition. From Incyte's Opzelura, the first FDA-approved drug for vitiligo, to Temprian Therapeutics’ DNA-based treatments and Clinuvel’s synthetic hormones for full-body repigmentation, we explore the innovations redefining the field.  

Learn how industry leaders like Amgen and Pfizer are moving beyond cosmetic solutions with advanced targeted therapies. Amgen’s AMG-714 blocks interleukin-15 to protect melanocytes, while Pfizer’s oral drug Litfulo targets immune pathways for systemic repigmentation. We also delve into the role of AI in diagnostics, featuring Skinopathy’s groundbreaking collaborations.  

This episode captures the excitement and momentum driving vitiligo research and development. With these advancements, the future looks promising for more effective, accessible, and personalized treatments. Join us for an insightful dive into the breakthroughs offering hope to millions.

In a world where even dogs have podcasts, it’s time for vitiligo to have its own voice—enter Deep Dive in Vitiligo, a weekly news digest from the frontiers of medicine and science, brought to you by Yan Valle, CEO of the Vitiligo Research Foundation.  

In this debut episode, we set the stage for what this podcast is all about: shedding light on the latest breakthroughs in vitiligo research, debunking myths, and giving this often misunderstood condition the attention it deserves.  

What’s really driving the recent wave of innovations? Are we on the brink of discovering a cure? And how can patients, advocates, and scientists work together to create lasting change? This first episode is your invitation to join a global conversation that will challenge perceptions and inspire action. Whether you’re newly diagnosed, a long-time advocate, or just curious about vitiligo, Deep Dive in Vitiligo is here to be your trusted guide.